Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Anneke van der Walt et al.|JAMA Neurology|2023Cited by 62
Updated Results of the COVID-19 in MS Global Data Sharing InitiativeSteve Simpson, Liesbet M. Peeters, Ashkan Pirmani et al.|Neurology Neuroimmunology & Neuroinflammation|2022Cited by 53
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Mathilde Lefort et al.|CNS Drugs|2021Cited by 12
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson, Tomáš Kalinčík, Ashkan Pirmani et al.|Multiple Sclerosis and Related Disorders|2022Cited by 7